Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?

Emre Yekedüz, Güngör Utkan, Ravindran Kanesvaran, Yüksel Ürün

Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey
Division of Medical Oncology, National Cancer Center, Singapore

Abstract

Prostate cancer (PCa) is the most common cancer in men. Androgen receptor axis plays a crucial role in the carcinogenesis of PCa. The mainstay treatment of prostate cancer is blockage of androgen receptor axis but in a vast majority of patient resistance to androgen deprivation therapy is inevitable. After using enzalutamide, the first new generation anti-androgen (AA), two new generation AA drugs were synthesized. New generation anti-androgen drugs are used especially in castration resistance prostate cancer. But recently, there are new publications regarding using new generation anti-androgens in castration sensitive prostate cancer patients. In this review, we will compare structure, mechanisms of effect and clinical outcomes in phase 3 trials of these new generation AA drugs.

Keywords:
Androgen Receptor Antagonists
Androgen-Resistant Prostatic Cancer
Prostatic Neoplasms

1. Introduction

Prostate cancer (PCa) is the most common cancer in men in accordance with GLOBOCAN 2018. In 2019, 174,650 new cases will be seen and 31,620 patients will die from PCa in US. Androgen receptor (AR) is a member of steroid hormone receptor family and the AR axis plays a crucial role in the development of PCa. Androgen deprivation therapy (ADT) is mainstay of treatment for patients with PCa but the development of resistance is inevitable. There are several mechanisms causing this resistance. AR gene amplification, AR mutations, expression of AR splice variants, altered expression of AR coregulators, intratumoral androgen synthesis, and post-translational modifications of AR are the most well-known mechanisms of castration resistance. The first generation antiandrogens (AAs) such as bicalutamide have a partial agonistic effect on the AR, which is associated with its limited efficacy in castration-resistance setting. More recently studies of the new and more potent AA drug have established these novel therapies as new standards of care. The first novel nonsteroidal AA, enzalutamide, was approved in 2012. Thereafter, two new AA drugs, apalutamide and darolutamide, have established their roles in the treatment of nonmetastatic castration-resistance PCa (nmCRPCa). In the metastatic castration-resistance PCa (mCRPCa) setting, enzalutamide has an established role as well. In this review, we will compare structure, mechanisms of effect and clinical outcomes in phase III trials of these new generation AA drugs.

2. Structure and mechanisms of the effect

Enzalutamide (formerly MDV3100) is an oral nonsteroidal drug and the first of the novel AA. It is a diaryl thiohydantoin compound. It functions through several mechanisms for AR axis inhibition. It blocks interactions of androgen hormone and receptor, inhibits translocation of AR, binding DNA, and also inhibits coactivator recruitment. Unlike first generation AAs, enzalutamide has no agonistic effect on AR and its affinity to their receptor was five to eight-fold more than bicalutamide in vitro. When compared with bicalutamide, enzalutamide significantly improved oncological outcomes [reduced the risk of progression or death by 76% compared with bicalutamide (hazard ratio [HR], 0.24; 95% CI: 0.18 to 0.32; P < .001)]12. The mechanism of action of the novel AAs is shown in Figure 1.

Apalutamide (formerly ARN-509) is the second novel AA, and it is a synthetic diaryl thiohydantoin compound such as enzalutamide. Although it has lower steady-state plasma concentrations, preclinical investigations showed that apalutamide was more effective than enzalutamide. All nonsteroidal AAs bind gamma-aminobutyric acid A receptors, thus seizures occur as an
uncommon but severe adverse effect of these agents. However, when compared with enzalutamide, apalutamide has less seizure risk because it has 4-fold lower levels in the brain. In addition, plasma concentrations of apalutamide were lower than enzalutamide but intratumoral concentrations were higher. Plasma free fraction level of apalutamide was higher than enzalutamide because of it is less protein bound.

Darolutamide (formerly ODM-201) is the newest novel AA drug. Chemical structure of this agent is different from the other new generation AAs. Its active metabolite is ORM-15341. Darolutamide shows its effect by inhibiting AR similarly to enzalutamide and apalutamide. Darolutamide and its active metabolite have more potent efficacy on AR when compared to enzalutamide and apalutamide. However, darolutamide has full antagonistic effect despite mutations of AR. Moreover, in preclinical investigations it is observed that darolutamide and its metabolite have a lower level of brain/plasma ratio than enzalutamide and apalutamide. In addition, unlike enzalutamide, darolutamide does not increase levels of serum testosterone because of effect on hypothalamic-pituitary-gonadal axis. This may contribute to better efficacy of this drug.

3. Landmark phase III trials of novel AAs

Enzalutamide is the first new generation AA drug. The first phase III trial of enzalutamide was the AFFIRM trial. This trial displayed the effect of enzalutamide on patients with mCRPC who were previously treated with docetaxel. There was a risk reduction of death of 37% in patients treated with enzalutamide. There were 5 months difference between groups given enzalutamide or placebo in terms of overall survival (OS) [18.4 months vs 13.6 months (HR: 0.63; 95% CI: 0.53-0.75; p < 0.001), respectively], as well. In the enzalutamide group, median radiographic progression-free survival (rPFS) was 8.3 months and median time to first skeletal-related event was 16.7 months (HR: 0.40; 95% CI: 0.35-0.47; p < 0.001). Compared with placebo, there were more fatigue, diarrhea, musculoskeletal pain, and headache in enzalutamide group and also seizures were 6% (5 of the 800 patients) vs 0% of the patients on placebo.

A randomized phase III PREVAIL trial showed the effect of enzalutamide on mCRPC before chemotherapy. When compared with the placebo in patients treated with enzalutamide, the risk reduction of death was 29% (HR: 0.71; 95% CI: 0.60-0.84; p < 0.001) and median OS was 32.4 months. Median rPFS was not reached in the treatment arm vs 3.9 months in the placebo group. Fatigue was the most common adverse event in enzalutamide group and was similar to that seen in the AFFIRM trial. Hence, enzalutamide was proven as an effective agent for mCRPC both before or after chemotherapy.

Enzalutamide was approved by the Food and Drug Administration (FDA) in 2012 after the AFFIRM trial for patients with mCRPC who had previously been treated with docetaxel, and in 2014 after the PREVAIL trial for chemotherapy naive patients. In 2018, a randomized phase III trial, showed the benefit of enzalutamide in patients with nmCRPCa. In contrast to the AFFIRM and the PREVAIL trials, the primary end point was metastasis-free survival (MFS), which was a new FDA-approved end point for PCa. Median MFS was 36.6 months vs 14.7 months (HR: 0.29; 95% CI: 0.24-0.35; p < 0.001) in enzalutamide and placebo groups, respectively. The median time to PSA progression was 36.6 months vs 14.7 months (HR: 0.07; 95% CI: 0.05-0.08; p < 0.001) in enzalutamide and placebo groups, respectively. Similar to the AFFIRM and the PREVAIL trials, the most common side effect that has been observed was fatigue and hypertension in the enzalutamide group.

Darolutamide is the newest novel AA for CRPC was darolutamide. Darolutamide has a different structure from the other new generation AAs. The primary end point of this trial was MFS similar to the PROSPER trial. Median MFS was 40.4 months vs 16.6 months (HR: 0.27; 95% CI: 0.22-0.34; p < 0.001) in apalutamide and placebo groups, respectively. The median time to PSA progression was not reached vs 3.7 months (HR: 0.06; 95% CI: 0.05-0.08; p < 0.001) in apalutamide and placebo groups, respectively. This trial also showed that after starting treatment for mCRPC, median time until second progression was longer in patients with previously given apalutamide. Recently, interim OS analysis of SPARTAN trial has been announced and it was shown that darolutamide had 25% reduction risk for OS. The most common adverse event was fatigue like enzalutamide. Seizures were seen in two patients in apalutamide group, however there was no patients with seizures in placebo group.

The newest novel AA drug for CRPC was darolutamide. Darolutamide is the second approved novel AA in patients with nmCRPCa after the SPARTAN trial. The primary end point of this trial was MFS similar to the PROSPER trial. Median MFS was 40.4 months vs 16.6 months (HR: 0.27; 95% CI: 0.22-0.34; p < 0.001) in apalutamide and placebo groups, respectively. The median time to PSA progression was not reached vs 3.7 months (HR: 0.06; 95% CI: 0.05-0.08; p < 0.001) in apalutamide and placebo groups, respectively. This trial also showed that after starting treatment for mCRPC, median time until second progression was longer in patients with previously given apalutamide. Recently, interim OS analysis of SPARTAN trial has been announced and it was shown that darolutamide had 25% reduction risk for OS. The most common adverse event was fatigue like enzalutamide. Seizures were seen in two patients in apalutamide group, however there was no patients with seizures in placebo group.
fracture risk were similar in darolutamide and placebo groups, however the PROSPER and the SPARTAN trials showed higher falls rates in enzalutamide and apalutamide groups compared with placebo groups.6,7,17. Hypertension and coronary artery disease were similar in darolutamide and placebo groups, however hypertension was more frequent in enzalutamide and apalutamide groups than placebo groups.6,7,17. Summary of grade III-IV adverse events of new AAs among patients with CRPCa are shown in Table 2. Furthermore, adverse events leading to discontinuation of the trial regimen were similar in darolutamide and placebo groups but higher in enzalutamide and apalutamide groups compared with placebo groups.6,7,17.

Owing to there were three novel AAs, we had only enzalutamide in the metastatic setting and it was only used in the castration-resistant group. The benefit of enzalutamide and apalutamide has also recently been shown in patients with metastatic castration-sensitive PCa.22,23. In May 2019, results of the TITAN trial, which showed the effect of apalutamide plus ADT among patients with mCSPC, were published. This study showed, the median rPFS was not reached vs 22.1 months (HR: 0.48; 95% CI, 0.39-0.60; p < 0.001) in apalutamide and placebo groups, respectively. The OS at 24 months was 82.4% vs 73.5% (HR: 0.67; 95% CI: 0.51-0.89; p = 0.005) in apalutamide and placebo groups, respectively. After subsequent therapy owing to disease progression, the second median PFS was better in the group of patients who were on apalutamide (HR: 0.66; 95% CI: 0.50-0.87). However, subgroup analysis revealed that the effect of apalutamide plus ADT was not seen in patients with mCSPC previously treated with docetaxel and who had low volume disease. The most common side effect was rash in apalutamide group. However, the percentage of fall and seizure were similar in both groups. Furthermore, when compared grade III-IV side effects of apalutamide or placebo treatment, the percentage of patients who had grade III-IV toxicities was similar and it was 42.2% vs 40.8% in apalutamide and placebo groups, respectively. The quality of life was similar in both groups and there was no substantial difference in the Functional Assessment of Cancer

Table 1
Clinical outcomes of the new-generation antiandrogens in nonmetastatic castration-resistance prostate cancer patients

| Efficacy endpoints | PROSPER (N = 933) | SPARTAN (N = 806) | ARAMIS (N = 955) |
|-------------------|-------------------|-------------------|------------------|
| mMFS (months)     | 36.6              | 40.5              | 40.4             |
| HR, (95% CI)      | 0.29 (0.24-0.35, p < 0.001) | 0.28 (0.23-0.35, p < 0.001) | 0.41 (0.34-0.50, p < 0.001) |
| Median time to PSA progression (months) | 37.2              | NR                | 33.2             |
| HR, (95% CI)      | 0.07 (0.05-0.08, p < 0.001) | 0.06 (0.05-0.08, p<) | 0.13 (0.11-0.16, p < 0.001) |
| mOS (months)      | NR                | NR                | NR               |
| HR, (95% CI)      | 0.80 (0.58-1.09, p = 0.15) | 0.70 (0.47-1.04, p = 0.07) | 0.71 (0.50-0.99, p = 0.045) |
| mPFS (months)     | N/A*              | 40.5              | 36.8             |
| HR, (95% CI)      | 0.29 (0.24-0.36, p < 0.001) | 0.38 (0.32-0.45, p < 0.001) |                   |

mMFS – median metastasis-free survival, mOS – median overall survival, mPFS – median progression-free survival, HR – hazard ratio, CI – confidence interval, PSA – prostate-specific antigen.

*Data not available.
In June 2019, the ENZAMET trial, which showed the effect of enzalutamide plus ADT in patients with mCSPC, was published. In contrast to the TITAN trial, enzalutamide plus ADT was compared with nonpotent AA such as bicalutamide, nilutamide or flutamide plus ADT in this trial. The ENZAMET study showed OS was higher in enzalutamide plus ADT group with a percentage at 3 years of 79% vs 72% compared with standard of care (SOC) group. PSA and clinical PFS was better in enzalutamide plus ADT group compared with SOC group. The percentage of PSA PFS at 3 years was 67% vs 37% and the percentage of clinical PFS at 3 years was 68% vs 41% in enzalutamide and SOC groups, respectively. After subsequent therapy due to disease progression, the percentage of patients with progressive disease was lower in the group of patients who had imposed enzalutamide than SOC in the first line setting (67% vs 85% in enzalutamide and SOC groups, respectively). However, there was no difference with respect to OS between enzalutamide and SOC groups among subgroup of patients with high volume disease and visceral metastasis (adjusted p values were 0.14 and 0.33, respectively). The percentage of serious adverse events were 42% vs 34% in enzalutamide and SOC groups, respectively. As expected, seizure was more common in enzalutamide group than SOC group and 7 patients in enzalutamide group had seizure. In the TITAN and the ENZAMET trials, have shown that using novel AAs plus ADT was more effective in terms of OS and PFS than using ADT alone or ADT plus nonpotent AAs in the patients with mCSPC.

4. Conclusion

Our treatment armamentarium for the treatment of advanced PCa has expanded rapidly in the last few years. These agents have not only improved survival but also led to improvements in Quality of life (QOL) for all our patients. However, the lack of phase III comparative studies has made it hard to make decisions on the best therapy or sequence of these novel agents in the respective settings. Upcoming studies (such as PEACE 1), may help answer some of these questions (NCT01957436) and provide us with important answers on sequencing.

Conflicts of interest

The authors declare no conflict of interest.

References

1. Bravaccini S, Puccetti M, Bocchini M, Ravaoli S, Celli M, Scarpi E, et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep 2018;8:4254.
2. Handy CE, Antonarakis ES. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 2018;14:907–17.
3. Wang D, Tindall DJ. Androgen action during prostate carcinogenesis. Methods Mol Biol 2011;776:25–44.
4. Huang Y, Jiang X, Liang X, Jiang G. Molecular and cellular mechanisms of castration resistant prostate cancer. Oncol Lett 2018;15:6063–76.
5. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787–90.
6. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide Treatment and Metastasis-Free Survival in Prostate Cancer. N Engl J Med 2018;378:1408–18.
7. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2019;380:1295–46.
8. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–33.
9. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–97.
10. Hoffman-Censits J, Kelly WK. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Canc Res 2013;19:1335–9.
11. Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Canc Res 2011;17:3876–83.
12. Penson DF, Armstrong AJ, Conception R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol 2016;34:2098–106.
13. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Canc Res 2012;72:1494–503.
14. Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, et al. Disruption of PSA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep 2018;8:4254.
15. Ning YM, Brave M, Karsh L, Tang S, Shi V, Sridhara R, et al. Androgen receptor expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep 2018;8:4254.
16. King L, Christie D, Arora D. Anoookumar-Duke S. Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study. Prostate Int 2020 Mar;8(1):34–40. https://doi.org/10.1016/j.prnil.2019.10.004. Epub 2019 Nov 30. PubMed PMID: 32257976; PubMed Central PMCID: PMC7125379.
17. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2018;378:555–74.
18. FDA Broadens Approval for Enzalutamide to Include Non-Metastatic Castration-Resistant Prostate Cancer. European Society for Medical Oncology (ESMO); 2018.
20. FDA approves apalutamide for non-metastatic castration-resistant prostate cancer. U.S. Food & Drug Administration; 2018.

21. Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol 2019;30:1813–20.

22. Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2019 Jul 4;381(1):13–24. https://doi.org/10.1056/NEJMoa1903307. Epub 2019 May 31. PubMed PMID: 31150574.

23. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 2019 Jul 11;381(2):121–31. https://doi.org/10.1056/NEJMoa1903835. Epub 2019 Jun 2. PubMed PMID: 31157964.

24. Unicancer, Janssen-Cilag L, , European Organisation for R, Treatment of Cancer E, Ipsen Sanofi. A Phase III Study for Patients With Metastatic Hormone-naive Prostate Cancer 2019.